- Investing Ideas
- U.K. Pharmaceuticals & Biotech Pure Equity Growth
U.K. Pharmaceuticals & Biotech Pure Equity Growth
Results
9
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
9 companies
Corcept Therapeutics
Market Cap: US$9.6b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
0I3Q
US$88.53
7D
-4.0%
1Y
21.8%
Camurus
Market Cap: SEK 36.6b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
0RD1
SEK 608.79
7D
9.6%
1Y
-11.4%
Camurus
Market Cap: SEK 36.6b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMXS
SEK 615.75
7D
9.2%
1Y
n/a
BioArctic
Market Cap: SEK 27.5b
Develops biological drugs for patients with central nervous system disorders in Sweden.
0RV2
SEK 311.93
7D
-2.8%
1Y
65.6%
BioArctic
Market Cap: SEK 27.5b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOABS
SEK 328.70
7D
0%
1Y
n/a
Bonesupport Holding
Market Cap: SEK 14.4b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEXS
SEK 219.70
7D
-4.3%
1Y
-30.6%
Bonesupport Holding
Market Cap: SEK 14.4b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
0RQO
SEK 225.58
7D
0.5%
1Y
-28.0%
Kuros Biosciences
Market Cap: CHF 848.4m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURNz
CHF 21.39
7D
0.1%
1Y
-26.3%
Kuros Biosciences
Market Cap: CHF 848.4m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
0RHR
CHF 21.24
7D
-0.7%
1Y
-26.9%